Induction of immunogenic cell death by novel platinum-based anticancer agents. (January 2023)

• Record Type: Journal Article
• Authors: Chang, Xingyu; Bian, Mianli; Liu, Lijuan; Yang, Jiaqi; Yang, Zhibin; Wang, Zhaoran; Lu, Yunlong; Liu, Wukun
• Is Part Of: Pharmacological research. Volume 187(2023)
• Publication Date: 2023-01
• Subjects: STAT6 transcription 6 -- ICD immunogenic cell death -- OCTs organic cation transporter -- CTR1 copper transport protein 1 -- DAMPs damage-related molecular patterns -- ERS endoplasmic reticulum stress -- CRT calreticulin -- ATP adenosine-triphosphate -- HMGB1 high mobility group box 1 protein -- P2RX7 7 purinergic receptor P2X -- TLR4 toll like receptor 4 -- DC dendritic cells -- IL-1β interleukin-1β -- IL-17 interleukin-17 -- IFN-γ interferon-γ -- CTL cytotoxic T cells -- ER endoplasmic reticulum -- eIF2α eukaryotic initiation factor α -- ROS reactive oxygen species -- PERK protein kinase RNA-like endoplasmic reticulum kinase -- Bap31 B-cell receptor-associated protein 31 -- Bax Bcl2-associated X -- ATG5 autophagy-related gene 5 -- ATG7 autophagy-related gene 7 -- Beclin1 Bcl-2 Assaciated X protein -- LAMP1 autolysosome lysosomal associated membrane protein 1 -- P2Y2 2 purinergic receptor P2Y -- TLR toll-like receptors -- RAGE glycosylation end product receptor -- APC activating antigen-presenting cells -- TGF-β transforming growth factor-β -- IC inflammatory cytokines -- POA 2-(2-propynyl)octanoic acid -- HDACi histone deacetylase inhibitor -- UPR unfolded protein response -- RNS reactive nitrogen species; Oxaliplatin -- Platinum derivatives -- Immunogenic cell death -- Anticancer Cisplatin (PubChem CID -- 5702198) -- Carboplatin (PubChem CID -- 426756) -- Oxaliplatin (PubChem CID -- 9887053) -- R, R-1, 2 cyclohexanediamine-pyrophosphato-platinum(II) (PubChem CID -- 252–41709) -- [1, 3-diethyl-4, 5-bis(4-fluorophenyl)− 2-imidazol][pyridine]-diiodoplatinum(II) (PubChem CID -- 163196301); Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2022.106556
• Languages: English
• ISSNs: 1043-6618

Abstract

Abstract: Traditional platinum-based anticancer drugs, led by cisplatin, play an important role in chemotherapy. However, the development of platinum compounds is limited due to serious toxicity and side effects. In recent years, studies have showed that immunogenic cell death (ICD) may be one of the potential action mechanisms of classical platinum drugs, such as oxaliplatin. This strategy combining chemotherapy and immunotherapy can effectively utilize the body's immune system to help platinum compounds to fight against tumors, and the dose can be appropriately reduced to limit toxic side effects. The induction of ICD by platinum compounds has become a research hotspot and one of the future development directions of metal drugs. Here, the progress of platinum compounds were collected and comprehensively summarized, their capacity of ICD induction and mechanism of action are exposed, providing reference for the design and synthesis of new anticancer platinum ICD inducers. Graphical Abstract: ga1